文献速递浆细胞疾病

泛素激活酶抑制诱导未折叠蛋白反应并克服骨髓瘤耐药

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
PubMed 文献 · Blood · 2019-02-08

研究评估新型特异性泛素激活酶(UAE)抑制剂TAK-243在骨髓瘤中的活性。TAK-243抑制细胞系生长、诱导凋亡并激活内质网应激通路,在细胞系模型中克服硼替佐米和卡非佐米耐药,对复发/难治患者原代细胞有活性,与多种抗骨髓瘤药物强协同,并在体内模型中有效。

要点

  • TAK-243抑制骨髓瘤细胞系生长、诱导凋亡并激活caspase。
  • TAK-243在细胞系模型中克服硼替佐米和卡非佐米耐药。
  • TAK-243对复发/难治骨髓瘤患者原代细胞有活性。

核心结论

  • 数据支持UAE抑制可作为复发和/或难治多发性骨髓瘤患者推向临床的有吸引力的策略。

研究设计与样本

  • 体外研究评估TAK-243对骨髓瘤细胞系、原代细胞及体内骨髓瘤模型的作用。

主要发现

  • TAK-243有效抑制骨髓瘤细胞系生长、诱导凋亡并激活caspase,同时降低泛素-蛋白偶联物丰度。
  • TAK-243稳定包括p53、MCL-1和c-MYC在内的多种短寿命蛋白,并激活ATF-6、IRE-1和PERK分支的内质网应激反应通路及氧化应激。
  • UAE抑制对野生型或p53缺失的等基因细胞系显示可比活性,尽管在野生型细胞中诱导TP53信号。
  • TAK-243在细胞系模型中克服对硼替佐米和卡非佐米的耐药,并对复发/难治骨髓瘤患者原代细胞有活性。
  • TAK-243与多柔比星、美法仑和帕比司他等抗骨髓瘤药物显示强协同(低联合指数),并在多个体内骨髓瘤模型中有效伴内质网应激激活。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Three proteasome inhibitors have garnered regulatory approvals in various multiple myeloma settings; but drug resistance is an emerging challenge, prompting interest in blocking upstream components of the ubiquitin-proteasome pathway. One such attractive target is the E1 ubiquitin-activating enzyme (UAE); we therefore evaluated the activity of TAK-243, a novel and specific UAE inhibitor. TAK-243 potently suppressed myeloma cell line growth, induced apoptosis, and activated caspases while decreasing the abundance of ubiquitin-protein conjugates. This was accompanied by stabilization of many short-lived proteins, including p53, myeloid cell leukemia 1 (MCL-1), and c-MYC, and activation of the activating transcription factor 6 (ATF-6), inositol-requiring enzyme 1 (IRE-1), and protein kinase RNA-like endoplasmic reticulum (ER) kinase (PERK) arms of the ER stress response pathway, as well as oxidative stress. UAE inhibition showed comparable activity against otherwise isogenic cell lines with wild-type (WT) or deleted p53 despite induction of TP53 signaling in WT cells. Notably, TAK-243 overcame resistance to conventional drugs and novel agents in cell-line models, including bortezomib and carfilzomib resistance, and showed activity against primary cells from relapsed/refractory myeloma patients. In addition, TAK-243 showed strong synergy with a number of antimyeloma agents, including doxorubicin, melphalan, and panobinostat as measured by low combination indices. Finally, TAK-243 was active against a number of in vivo myeloma models in association with activation of ER stress. Taken together, the data support the conclusion that UAE inhibition could be an attractive strategy to move forward to the clinic for patients with relapsed and/or refractory multiple myeloma.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zhuang J, Shirazi F, Singh RK, et al. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. Blood. 2019. PMID: 30737236. doi:10.1182/blood-2018-06-859686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。